KMI vs RIGL · P/E 24, rev $9.30B vs P/E 9.1, rev $137.5M
Kinder Morgan Inc (KMI) versus Rigel Pharmaceuticals Inc (RIGL) — a side-by-side from cached financials, not a winner call.
Kinder Morgan Inc (KMI) is a oil & gas midstream company listed on US.
Rigel Pharmaceuticals Inc (RIGL) is a biotechnology company listed on US.
Latest reported KMI revenue for 2026-06-30 was $9.30B. Net income was $1.84B. Revenue was up 92.7% from 2026-03-31 to 2026-06-30. KMI currently screens at market cap $62.53B and trailing P/E 24.2.
Latest reported RIGL revenue for 2026-06-30 was $137.5M. Net income was $25.9M. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
KMI currently screens at market cap $62.53B and trailing P/E 24.2. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
Not investment advice. Open the KMI and RIGL stock pages for the full models.
Not investment advice.